Market Trends of Smart Inhalers Industry
The Metered Dosage Inhalers (MDI) Segment is Expected to Dominate the Smart Inhalers Market During the Forecast Period
MDIs are inhalation devices that deliver medication in a precisely measured spray or mist. They are propelled by a propellant, and patients should coordinate their breath with inhaler actuation. In most cases, MDIs are preferred due to their familiarity and ease of use. Many pharmaceutical companies and inhaler manufacturers are integrating smart features into MDIs, making them attractive options for patients who are looking to enhance medication adherence and disease management. For instance, AstraZenca's Symbicort Inhaler incorporates inhaler analytics to track usage and provide feedback to patients in order to enhance medication adherence.
Ongoing technological advancements and product approvals for MDI-based smart inhalers are further projected to propel the market. Technological benefits, such as dose counters, inhaler analytics, and integration with mobile apps, contribute to MDIs' dominance in the smart inhalers market. For instance, in February 2022, HeroTracker Sense was designed to improve the lives of patients with chronic respiratory disease caused by COVID-19. It helped track their MDI usage and facilitate improved adherence to their prescribed therapy.
Therefore, the MDI-based smart inhalers segment is expected to dominate over the forecast period due to major factors such as the growing emphasis on patient-centric healthcare, technological advancements enhancing inhaler effectiveness, and rising product approvals involving the integration of digital health solutions into respiratory care. These drivers collectively underscore the promising trajectory of MDIs within the dynamic landscape of smart inhalers.
North America is Expected to Dominate the Smart Inhalers Market
North America is expected to dominate the market owing to factors such as the high prevalence of respiratory diseases, rapid growth in advanced technologies, and robust healthcare infrastructure in the region.
The prevalence of respiratory diseases, such as asthma and COPD, is substantial in North America. As per the Asthma and Allergy Foundation of America, in 2023, more than 27 million people in the United States had asthma, equaling about 1 in 12 people. Moreover, as per the same source, more than 22 million United States adults aged 18 and older had asthma. Furthermore, according to the Centers for Disease Control and Prevention (CDC), cases of asthma in children have declined from 2001 through 2020. However, it was estimated that 50% of children had uncontrolled asthma.
North American companies and research institutions have been at the forefront of developing smart inhaler technology. Key product launches and the high concentration of market players in the United States are some of the factors driving the growth of the smart inhalers market in the country. For example, Propeller Health, a US-based firm, developed a platform with smart inhalers and sensors for asthma and COPD management. The US Food and Drug Administration (FDA) has been actively involved in regulating smart inhaler devices. In 2021, BreatheSuite Inc., a connected respiratory health company in Canada, received the 510(K) clearance from the US FDA for its BreatheSuite metered-dose inhaler (MDI) V1 device.
Therefore, owing to the aforesaid factors, the market studied is anticipated to witness growth in North America.
